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2ABSTRACT
Urinary Excretion of (1→3)-β-D-Glucans
by
Debra K Head 
(1→3)-β-D-Glucans are carbohydrate polymers that are present in the cell wall of various fungi 
and bacteria; they are pathogen associated molecular patterns that circulate during infection and 
modulate immunity.  Our laboratory has previously established the pharmacokinetics of 
intravenously and orally administered glucans; the present studies investigated the renal 
excretion of (1→3)-β-D-glucans following intravenous and oral administration.  Three 
fluorescently-labeled glucans were administered to adult male rats in the presence or absence of 
toxic challenge. Urine specimens were collected and analyzed by fluorescence spectroscopy, 
size-exclusion chromatography and GPC/MALLS.  71 ± 3% of fluorescence remained in the 
>5K MWCO fraction; this fraction showed a minor peak with a molecular mass (171 ± 11K) 
corresponding to injected glucan (~150K). Most excreted glucans were of lower molecular mass 
(13 ± 8.5K), indicating most (1→3)-β-D-glucans are excreted by the kidneys as smaller 
polysaccharides.   The presence of urinary glucans may be an important indicator of fungal 
infection.
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CHAPTER 1
INTRODUCTION
Overview of Renal Function
All living organisms require some method of balancing nutrients and water obtained from 
their food sources while excreting waste, or unnecessary substances, along with water.  In most 
animals, this method is the renal system.  The kidneys are the main component of the renal 
system; their function is to filter, reabsorb, and secrete water and nutrients between the 
peritubular blood vessels and the nephron to maintain homeostasis.  Under normal conditions in 
humans, approximately 1200 mL of blood passes through kidneys every minute, which is equal 
to 20% of the total cardiac output.  Of that, 650 mL/min is plasma.  Approximately 20% of this 
plasma flow is filtered into the nephron, amounting to 180 L/day of filtered plasma at a 
glomerular filtration rate (GFR) of 125 mL/min (Costanzo 2006).  It is evident from these 
statistics that the kidneys are essential for filtering the blood in our systems.
There are three major processes that occur within the nephron.  First, filtration occurs 
between the glomerular capillaries and Bowman’s capsule of the nephron.  During this process, 
plasma is filtered into the nephron (according to the GFR mentioned above), containing all but 
the molecules with the highest molecular weights.  The unfiltered plasma continues from the 
glomerular capillary into the efferent arteriole, which leads to the peritubular capillaries.  Here, 
the second process of reabsorption takes place.  The vast majority of the water and nutrients that
were filtered into the nephron are reabsorbed back into the peritubular capillaries; for many 
substances, this occurs at a rate of 99% or more reabsorption and is an energy-dependent 
process, using active transport mechanisms.  Sodium is the primary ion reabsorbed along the 
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nephron; it is vital in maintaining fluid balance, and in turn, normal blood pressure and volume.  
Within the peritubular capillaries, secretion can also take place, which is the third process.  The 
main purpose of secretion is to rid the unfiltered plasma fraction of waste products and unneeded 
substances, which are then excreted as urine (Costanzo 2006).
Fluid balance in the kidneys is driven by osmotic and hydrostatic pressures, collectively 
referred to as Starling forces.  These pressures are responsible for equilibrium between net 
filtration and net reabsorption of substances within the vasculature of the kidney; however, 
Starling forces are also responsible for the interdependent high filtration rate at the glomerular 
capillary and high reabsorption rate at the peritubular capillary.  The membrane sodium gradient 
and electrochemical gradient also play a role in regulating reabsorption and secretion; the 
sodium-potassium ATPase (Na/K ATPase) is the major force driving the transport of all other 
substances in the kidney (Costanzo 2006).
There are different segments within the nephron; each segment has a unique cell type 
with various transport mechanisms.  The early proximal tubule cells contain Na+ co-transporters 
specific for glucose, amino acids, and phosphate/lactate/citrate, as well as a Na+/H+ antiporter; 
these are all driven by the primary active transporter Na+/K+ ATPase.  Approximately 99% of 
filtered glucose and amino acids are reabsorbed in this segment.  The late proximal tubule cells 
contain parallel sodium-proton (Na+/H+) and chlorine-base (Cl-/Base) antiporters that result in 
paracellular reabsorption of Cl-, which brings with it cations such as Na+, Ca2+, and Mg2+.  When 
sodium balance and potassium balance exist, as under normal conditions, approximately 67% of 
filtered Na+ and K+ are reabsorbed through the early and late proximal tubule (Costanzo 2006).
The loop of Henle follows the late proximal tubule and is unique in that only one section 
of its three participates in active transport.  The thin descending limb is water-permeable but
12
ion-impermeable, resulting in net reabsorption of water.  The thin ascending limb is water-
impermeable, causing a passive reabsorption of Na+ to maintain osmotic balance.  Only the cells 
of the thick ascending limb contain an active transporter, the Na+/K+/2Cl- cotransporter, even 
though this section is also water-impermeable.  Potassium diffuses from these cells back into 
both the lumen of the nephron and into the capillary.  Passive paracellular reabsorption of cations 
such as Mg2+ and Ca2+ also occurs in this segment (Costanzo 2006).
The early distal tubule remains relatively water-impermeable and contains one 
cotransporter for Na/Cl.  The late distal tubule consists of two cell types: the α-intercalated cell 
and the principle cell.  The α-intercalated cell is primarily responsible for K+ reabsorption, and 
contains a proton pump as well as a H+/K+ antiporter.  The principle cell is primarily responsible 
for K+ secretion via increased lumen membrane permeability to both K+ and Na+.  These 
mechanisms are important in maintaining potassium balance in the presence of changes in 
dietary K+ intake; potassium balance must be maintained to ensure proper functioning of 
excitable tissues such as nerves, cardiac muscle, and skeletal muscle (Costanzo 2006).
Filtration of proteins and dextrans, or glucose polymers, from the glomerulus into 
Bowman’s capsule is dependent on molecular size. The glomerular capillary poses a number of 
size-limiting obstacles to filtration.  The endothelial membrane of the capillary wall is the least 
limiting, containing pores approximately 70-100 nm large (Costanzo 2006).  This size allows for 
the passive filtration of most solutes, including plasma proteins such as albumin, but not blood 
cells.  However, the rest of the capillary wall - the three-layer basement membrane and the 
epithelial wall - prevent further filtration of plasma proteins and other similarly sized molecules.  
The epithelium contains filtration slits, which are smaller than the pores of the endothelium at 
only 25-60 nm diameter (Costanzo 2006).  In addition to size, molecular charge also affects 
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filtration capability due to glycoproteins throughout the glomerular capillary wall.  These 
glycoproteins carry a negative electrostatic charge, thus attracting positively charged molecules 
and repelling those with a negative charge.  This “charge barrier” further inhibits filtration of 
plasma proteins that are negatively charged.  Dextrans are variably affected by these barriers, as 
their size can vary greatly depending on the number of glucose subunits and the conjugate; most 
dextran preparations used in clinical applications are between 40,000 to 70,000 Da.  In addition, 
a study published by Asgeirsson et al. (2007) reported that polysaccharides such as dextrans
appear to be more permeable across the glomerular capillary due to their linearity; they are less 
hindered by pore size barriers than the globular protein.   As discussed in the following section, 
glucans are also linear polysaccharides and likely conform to the same permeability as dextrans.
Chemistry of (1→3)-β-D-Glucans
Glucans are carbohydrate polymers that are a component of the cell wall in various 
pathogenic and saprophytic fungi such as Aspergillus species, Candida albicans, Saccharomyces 
cerevisiae, and the shiitake mushroom Lentinula edodes.  These polysaccharides are composed 
of multiple D-glucose subunits connected by 1,3 linkages; many glucans also have side chain 
branches linked at the 1,6 position.  In 2001, Douglas reported on the synthesis of fungal (1→3)-
β-glucans catalyzed by the plasma membrane enzyme UDP-glucose (1→3)-β-D-glucan β(3)-D-
glucosyltransferase. Essentially, within the fungal organism, the enzyme reacts with UDP-
glucose as its intracellular substrate, producing linear β1,3-glucan chains that are released into 
the cell wall space and connected to chitin, via β1,4 linkages, to form the cell wall.  During 
fungal infection, such as candidiasis or aspergillosis, these glucans are released into the patient’s 
systemic circulation (Miyazaki et al. 1995; Obayashi et al. 1995, 2008) and can be detected by 
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serum testing.  The most common assay, the G-test, employs Limulus, a (1→3)-β-D-glucan and 
lipopolysaccharide (LPS)-specific lysate from amebocytes of the horseshoe crab.  In 2008, 
Obayashi published data from autopsy cases that supported the use of clinical glucan serum tests 
in the diagnosis of mycotic infection; these assays for (1→3)-β-D-glucans have been tested and 
used clinically for several years.  However, Digby et al. (2003) had observed five years 
previously that this assay was not specific to fungal infection; in their studies, ICU patients with 
bacterial infections or polymicrobial infections also tested positive for serum (1→3)-β-D-
glucans. Interestingly, as a result of their 1995 study, Miyazaki et al. theorized that the release of 
β-glucans by the fungal organism may be a mechanism used to escape recognition by the host 
immune system.  They hypothesized that the polysaccharides might block phagocytic receptors 
for β-glucans.  It is now known that glucans have a wide variety of effects on the host immune 
system, which are described in greater detail below.
Glucans differ in their number of glucose subunits, degree of side chain branching, 
molecular mass, solution conformation, and polymer charge (Kulicke et al. 1997; Mueller et al. 
2000).  These variations influence the activity and receptor-ligand interactions of each glucan.
As described in Table 1, glucan phosphate is a mid-weight polysaccharide (157,000 Da) 
with no side chain branching (Fig. 1).  It has been employed extensively in vitro by our 
laboratory and several others in the study of glucan pharmacokinetics and biological activity. 
Laminarin is a small glucose polymer (7700 Da) with a side chain branching frequency of 
approximately 1:10 (Fig. 2).  Unlike glucan phosphate and scleroglucan, laminarin does not 
appear to have biological or immunological effects in vivo.  Both laminarin and glucan 
phosphate have a single helical solution conformation, as seen in Figure 3.  Scleroglucan is a 
polysaccharide with a large molecular mass of approximately 1,000,000 Da, higher than any 
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other synthetic glucan molecule employed by our laboratory.  It also has a high frequency of side 
chain branching, averaging 1:3.  Scleroglucan differs from glucan phosphate and laminarin in 
that it exists in solution as a triple helix (Fig. 4 and 5).
Table 1: Characteristics of three experimental glucans.  Adapted from Mueller et al. (2000) The 
influence of glucan polymer structure and solution conformation on binding to (1→3)-β-D-
glucan receptors in a human monocyte-like cell line.  Glycobiology 10:339-346. and Rice et al. 
(2002)  Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-β-D-
glucans.  J Leukoc Biol. 72:140-146.
Polysaccharide Molecular mass Degree of side chain branching Type of glycosidic linkage
Glucan phosphate 157,000 Da None β-(1→3)
Laminarin 7,700 Da 1:10 β-(1→3), (1→6) side chains
Scleroglucan ~1,000,000 Da 1:3 β-(1→3), (1→6) side chains
Polysaccharide Polymer charge Solution conformation
Glucan phosphate Weak polyanion Single helix
Laminarin Neutral Single helix
Scleroglucan Weak polyanion Triple helix
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Figure 1: Chemical structure of a 1→3-β linked glucose polymer with low level of side chain 
branching, similar to glucan phosphate.  Source: Adams et al. (2008) Differential high affinity 
interaction of dectin-1 with natural or synthetic glucans is dependent upon primary structure and 
is influenced by polymer chain length and side chain branching.  J Pharmacol Exp Ther.
325:115-23: used by permission.
Figure 2: Chemical structure of a 1→3-β linked glucose polymer with side chain branching at 
various positions, similar to laminarin. Source: Adams et al. (2008) Differential high affinity 
interaction of dectin-1 with natural or synthetic glucans is dependent upon primary structure and 
is influenced by polymer chain length and side chain branching.  J Pharmacol Exp Ther.
325:115-23: used by permission.
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Figure 3: End view of a single helical glucan structure.  When in solution, glucan phosphate and 
laminarin exist predominantly as single helices. Source: Williams et al. (2003) Recognition of 
fungal glucans by pattern recognition receptors.  Recent Devel Carbohydrate Res. 1:49-66: used 
by permission.
Figure 4: Chemical structure of a triple helical glucan polymer: three individual glucan polymer 
strands held together by hydrogen bonds at the C-2 hydroxyl at the center of the backbone chain, 
similar to scleroglucan. Used by permission from Williams (8 December 2008).
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Figure 5: End view of triple helical glucan structure, similar to scleroglucan.  Side chain 
branching is characteristic of scleroglucan but is not seen in this representation.  Source: 
Williams et al. (2003) Recognition of fungal glucans by pattern recognition receptors.  Recent 
Devel Carbohydrate Res. 1:49-66: used by permission.
In the last several years, the characterization of the chemical structures of various glucans 
has been augmented with the development of a nuclear magnetic resonance (NMR) spectroscopy 
assay specific for (1→3)-β-D-glucans by Lowman et al. (2001, 2003).  NMR spectroscopy 
allows for the identification and verification of chemical structures of proteins without affecting 
or destroying the sample.  This procedure analyzes the resonance frequency of nuclei in the 
molecule and converts those frequencies into chemical shift values, which can then be compared 
to a reference chemical shift, usually tetramethylsilane (Reusch 1991).  The glucan-specific 
NMR assay developed by Lowman and Williams in 2001 is based on the standard protein NMR 
analysis and provides a reliable, solvent-free method for identifying, characterizing, and 
quantitating the glucan dry-weight content within a matrix, such as extracts from a microbial or 
plant cell wall, without influencing any of their chemical or biological characteristics.  Their 
assay reduced the time needed to perform this analysis; previous methods of analyzing glucan 
content of a complex matrix required 1-2 days, whereas the NMR assay requires a few hours.
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Immunobiology of (1→3)-β-D-Glucans
Glucans are pathogen-associated molecular patterns or PAMPs.  PAMPs are defined as 
molecules or motifs shared by a related group of microorganisms but not associated with human 
or host cells. PAMPs interact with pattern recognition receptors (PRRs) within the innate 
immune system and cause numerous organism-dependent biological effects.  Common PAMPs 
include lipopolysaccharide A (LPS) and peptidoglycan; toll-like receptors are common PRRs.  
As pathogen-associated molecular patterns, glucans are known to interact with several cellular 
receptors throughout the body.  In 1985, Czop and Austin identified the first β-glucan-specific
receptor, a human monocyte receptor that influences the phagocytosis of activators of the 
alternative complement pathway.  Since that time, numerous glucan pattern recognition receptors 
(PRRs) have been characterized, including the type 3 complement receptor (CR3; Ross et al. 
1987; Thornton et al. 1996), scavenger receptors (Rice et al. 2002), and a C-type lectin-like 
receptor named Dectin-1 (Brown et al. 2001, 2002, 2003).  These receptors have been found on 
cells of the innate immune system such as macrophages, neutrophils, natural killer (NK) cells, 
dendritic cells, and some T cell subtypes (Brown and Gordon 2003, Williams et al. 2003), but 
also on cells throughout the body, including epithelial cells (Ahren et al. 2001), vascular 
endothelial cells (Lowe et al. 2002), fibroblasts (Kougias et al. 2001), and anterior pituitary cells 
(Breuel et al. 2004).  The observation of these receptors on non-immune cells indicates that 
glucans, in addition to causing indirect systemic responses through their interactions with 
immune system elements, may also directly affect the function of cells throughout the body 
(Kougias et al. 2001).
Glucans are biologically unique molecules.  They have been identified as a potential
target for antifungal pharmacological intervention; echinocandin drugs targeting (1→3)-β-D-
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glucans inhibit their synthesis, thus inhibiting cell wall formation and fungal growth (Onishi et 
al. 2001).  They have also been identified as potential pharmacologic substances themselves.  
Several researchers have investigated the numerous immunobiologic effects of β-glucans 
including anti-inflammatory and anti-cancer effects as described below.  
Glucans are known to stimulate and modulate the innate immune response through their 
interactions with various receptors.  For example, Dectin-1 has been identified as a major glucan 
receptor on macrophages, neutrophils, and dendritic cells; its interaction with glucans mediates 
phagocytosis of these polysaccharides (Herre et al. 2004).  This receptor is also responsible for 
the production of TNF-α during the inflammation response to yeasts and zymosan, another β-
glucan (Brown et al. 2003).  The glucan-receptor interaction effect is not limited to cells of the 
immune system, however.  In 2001, Kougias et al. published the first evidence for the presence 
of glucan-specific receptors and glucan binding sites on non-immune cells, in this case normal
human dermal fibroblasts (NHDF).  They discovered that glucans not only bind to specific sites 
on NHDF, they also enhance the activity of NF-κB and the genetic expression of 
proinflammatory cytokines through their interaction with these receptors.  This observation 
signifies that the body’s response to glucans may not be solely dependent upon cells of the 
immune system (Kougias et al. 2001).
β-Glucans have also been identified as anti-tumor polysaccharides.  Hong et al. (2004)
described the enhancement of the antitumor monoclonal antibody (mAb) effect by both yeast 
(1→3,1→6)-β-glucans and barley (1→3,1→4)-β-glucans.  When either glucan was administered 
orally, using a murine tumor model, the glucan was internalized by macrophages, degraded in 
the bone marrow, and taken up into granulocytes via CR3.  In contrast, intravenously-
administered (1→3)-β-glucans are taken up directly from the circulation by CR3 on 
21
granulocytes, as previously reported by Hong et al. (2003).  The presence of glucans within the 
granulocytes enhanced their ability to kill tumor cells coated with inactivated C3b (iC3b; 
deposited by natural antitumor antibodies).  This response, however, required the presence of 
CR3 on granulocytes and iC3b on tumor cells; if either was absent, tumor regression mediated by 
β-glucans and mAb did not occur.  Additional studies have found that β-glucans have a 
cytotoxicity-priming effect on cells other than granulocytes, including neutrophils and NK cells 
(Vetvicka et al. 1996).
Pharmacokinetics of (1→3)-β-D-Glucans
Our laboratory has investigated and characterized many of the pharmacokinetic 
properties of (1→3)-β-D-glucans following both intravenous and oral administration.  In 2004, 
Rice et al. investigated the pharmacokinetics of β-1,3-glucans after intravenous administration in 
a murine model.  They found that glucan phosphate demonstrated a longer half-life for 
elimination from plasma, a lower volume of distribution, and a lower plasma clearance rate than 
either scleroglucan or laminarin.  Their results indicate the possibility that some properties of 
glucans, i.e. molecular weight, solution conformation, or degree of branching, may influence 
their pharmacokinetic properties.  Select characteristics from this study are found in Table 2.
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Table 2. Pharmacokinetic characteristics for plasma laminarin, glucan phosphate and 
scleroglucan following intravenous administration.  Adapted from Rice et al. (2004) 
Pharmacokinetics of fungal (1-3)-beta-D-glucans following intravenous administration in rats.  
Int Immunopharmacol. 4:1209-15.
Parameter Laminarin Glucan phosphate Scleroglucan
Distribution half-life, min 3.7 ± 1.3 4.3 ± 0.7 2.1 ± 0.5
VD elimination, mL/kg 540 ± 146 350 ± 88* 612 ± 154
Half-life elimination, h 2.6 ± 0.2 3.8 ± 0.8§ 3.1 ± 0.6
Clearance, total, mL/kg/h 102.6 ± 17.4 41.9 ± 5.8*,§ 116.7 ± 18.9
Area under the curve (AUC),
mcg/mL/hr
10.6 ± 1.2 26.0 ± 3.4 9.5 ± 0.8
Laminarin and scleroglucan were administered 1 mg/kg; glucan phosphate was administered 
3.125 mg/kg.
*Significantly different from scleroglucan.
§Significantly different from laminarin.
Rice et al. (2005) also published the absorption and clearance of glucan phosphate, 
scleroglucan, and laminarin following oral administration in a murine model.  Several 
pharmacokinetic characteristics were elucidated in this study: maximum concentration peaks, 
clearance parameters, and biological effects including intestinal binding and increased survival 
rates in the presence of challenge with Staphylococcus aureus or Candida albicans.  Selected 
values are represented in Table 3.  In addition to these data, they reported glucan phosphate 
demonstrated peak concentrations in plasma at 4 hours following administration; laminarin 
demonstrated two peak concentrations at 3 hours and 12 hours following administration, as did 
scleroglucan at 15 min and 3 hours.  After 24 hours, 27 ± 3% of the maximum glucan phosphate 
level and 20 ± 7% of the maximum laminarin level remained in plasma; scleroglucan was 
virtually cleared from plasma at 12 hours, with approximately 5% of the maximum level 
remaining.  Rice et al. (2005) also observed that the expression of Dectin-1 (in gut-associated 
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lymphoid tissue, or GALT, cells) and TLR2 (in dendritic cells) increased after oral glucan 
administration.
Table 3.  Bioavailability of orally administered glucans.  Adapted from Rice et al. (2005) Oral 
delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to 
infectious challenge.  J Pharmacol Exp Ther. 314:1079-1086.
Parameter Laminarin Glucan phosphate Scleroglucan
Area under the curve (AUC), 
mcg/mL/hr
0.521 ± 0.147 0.120 ± 0.038 0.381 ± 0.229
Bioavailability, % 4.9% 0.5% 4.0%
Maximum concentration (Cmax),
ng/mL
115 ± 33 41.5 ± 3.4 355 ± 281
While the absorption and distribution of (1→3)-β-D-glucans has been characterized 
following both intravenous and oral administration, the method of excretion has not been 
elucidated.  Therefore, our studies were designed to test the hypothesis that intravenously- and 
orally-administered β-glucans are excreted by the kidneys but are metabolized into smaller 
polymers prior to renal processing to allow for filtration and secretion into the nephron and,
therefore, excretion in urine.
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CHAPTER 2
MATERIALS AND METHODS
Animals
Age- and weight-matched male Sprague-Dawley rats (Harlan Sprague-Dawley, 
Indianapolis, IN) were used.  Ages varied from 7 weeks to 16 weeks and weights varied from 
238 g to 456 g; however, both age and weight were matched within experimental groups.  
Animals were housed together in multiple cages, on a 12-hour light/dark cycle, with food and 
water available ad libitum.  Rats were weighed and fasted 18 hours prior to each experiment.  
Study protocol was approved by the University Committee on Animal Care, East Tennessee 
State University, Johnson City, Tennessee.
Glucans
(1→3)-β-D-Glucan phosphate was prepared and chemically characterized as previously 
described by Williams et al. (1991), Ensley et al. (1994), and Kim et al. (2000). Scleroglucan, a 
β-(1→3),(1→6)-glucan, was prepared and chemically characterized as previously described 
(Pretus et al., 1991). Laminarin, a β-(1→3),(1→6)-glucan, was purchased from Sigma-Aldrich 
(St. Louis, MO) and was chemically characterized as previously described (Mueller et al. 2000). 
The polymers were screened for endotoxin contamination with the Endospecy assay 
(Seikagaku/Cape Cod Associates, Falmouth, MA) according to manufacturer's instructions. 
Endotoxin levels were ≤0.3 IU/mg.
Preparation of Fluorescently Labeled Glucans
A diaminopropane (DAP) moiety was added to the reducing terminus of the glucan by 
the method of Kougias et al. (2001). Briefly, the DAP was attached to the reducing terminus of 
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the carbohydrate polymer by sodium borohydride reduction. The reaction mixture was dialyzed 
against 18-MΩ ultrapure pyrogen-free water and lyophilized to dryness. The glucan was stored 
at –20°C. Aliquots of the DAP-glucan derivatives were analyzed by gel permeation 
chromatography/multi-angle laser light scattering (GPC/MALLS), 1H NMR, and 13C NMR to 
confirm that the molecular weight, polydispersity, primary structure, and solution conformation 
were not altered by the derivatization.  The carbohydrates were labeled with one of three 
AlexaFluor succinimidyl esters: 488, 555 or 647 (Molecular Probes, Eugene, OR). Briefly, the 
amine reactive AlexaFluor succinimidyl ester (Pierce Chemical, Rockford, IL) was attached to 
the DAP moiety located at the reducing terminus. Specifically, DAP-glucan (3 mg) was 
dissolved into sodium borate buffer (0.1 M, pH 8.5) at a concentration of 10 µg/µl in a total 
volume of 300 µl. In the case of particulate glucan, the insoluble DAP glucan was suspended in 
borate buffer, and the suspension was maintained by gentle agitation. AlexaFluor 488, 555 or 
647 dye (5 mg) was dissolved in 35 µl of dimethyl sulfoxide. The dye solution was added to the 
DAP-glucan and incubated for 1 h in the dark, followed by addition of 300 µl of sodium borate 
buffer. The mixture was incubated overnight at ambient temperature on a reciprocating shaker at 
slow speed. The samples were incubated in foil-covered microfuge tubes to prevent exposure to 
light. The excess dye was removed by dialyzing (1000 Da molecular weight cutoff) against PBS 
overnight at room temperature. The advantage to this approach is that a single DAP and a single 
fluorescent moiety are attached to the reducing terminus of the polymer without changing the 
basic physicochemical characteristics of the carbohydrate ligand. Addition of the DAP and 
fluorescent tag does not alter binding of the glucan polymer to recombinant Dectin (data not 
shown). The labeling efficiency (>90%) was determined by flow cytometric analysis using 
recombinant Dectin-1.  
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Surgical Implantation of Microdialysis Catheter
All surgical instruments were sterilized in an autoclave (132 °C and 30 PSI for 15 
minutes) prior to surgery.  Sterile guide cannulae and probes were obtained from Bioanalytical 
Systems (MD-2212 and MBR-5, West Lafayette, IN).  Each rat was given an intraperitoneal 
injection of ketoprofen (1.0 mg/mL) 15 minutes prior to a 1:1 ratio of ketamine (100 mg/mL) 
and xylazine (20 mg/mL) injected intraperitoneally.  All injections were given in the volume of 
1% of body weight.   Once under anesthesia, the incision area was shaved and sterilized topically 
with alcohol.  The animal was then laid on a heating pad to maintain body temperature and 
placed into a stereotaxic instrument with its nose placed into a Kopf mask.  A mixture of 
isoflurane and oxygen was administered through the mask for the duration of the surgery to 
provide additional anesthesia and to aid in regular respiration.   A midline incision was made in 
the scalp using a sterile scalpel to expose the midline suture and the bregma landmark.  One 
complete intrusion was drilled into the skull using a Dremel Moto-Tool (Robert Bosch Tool 
Corporation, Racine, Washington) with a 1/32” bit at the coordinates 0.3 mm lateral and 1.5 mm 
caudal to bregma.  Two partial intrusions were also drilled approximately 1 mm from the 
complete intrusion.  Two skull screws were placed into the partial intrusions and anchored using 
ethyl cyanoacrylate to help anchor the acrylic cap used to hold the guide cannula in place.  The 
guide cannula was then lowered into the complete intrusion and dental acrylic was applied 
surrounding the cannula and the two screws and allowed to dry.  Once the acrylic was dry, the 
incision was closed with sutures.  The animal was then given 10 cc of sterile Ringer’s lactate
subcutaneously (SQ) for rehydration purposes and placed on the heating pad into a paper-towel-
lined cage until recovery from anesthesia was complete.  Once awake and alert, the animal was 
placed back into a bedding-lined cage with unlimited access to food and water.  Animals were 
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monitored following surgery for post-operative complications.  Three rats expired during the 
procedure; the other five survived and healed with no complications.
Preparation of Artifical Cerebrospinal Fluid
Sterile artificial cerebrospinal fluid (CSF) was prepared as described by Moghaddam et 
al. (1989).  Briefly, several 10X stocks were prepared in sterile 50 mL conical tubes, using 18 
MΩ deionized water.  These solutions were:
#1: 1450 mM NaCl (8.47g/100mL)
#2: 27 mM KCl (0.201g/100mL)
#3: 10 mM MgCl2●6H2O (0.203g/100mL)
#4: 20 mM Na2HPO4 (0.248g/100mL), pH 7.4
#5: 12 mM CaCl2●2H20 (0.176g/100mL)
On the day of use, 1.00 mL of each stock was combined in the order given and diluted to 
10 mL with 18 MΩ deionized water, mixed thoroughly, and filtered through a sterile 0.22µ filter 
into a sterile 50 mL conical tube.
Experimental Protocol for Laminarin Microdialysis
The surviving rats were given a 14-day recovery period following surgery.  On the day of 
microdialysis, the rats were sedated with isoflurane, then maintained on a combination of 
isoflurane and oxygen administered through a nose mask for the duration of the procedure, 
which provided constant anesthesia as well as assisting with regular respiration.  The animals 
were kept on a warm-water bed throughout the procedure to maintain proper body temperature.  
When the animal was under anesthesia, as determined by slow rhythmic breathing and lack of 
response to hindpaw pinching, an area approximately 4 cm in diameter at the lateral base of the 
neck was shaved and cleaned with 95% ethanol.   An incision was made to expose the right 
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jugular vein, and an intravenous line was established.  Placement of the line was verified by 
drawing back blood with the syringe before injecting approximately 1 cc of sterile Ringer’s 
lactate to flush the line.  A midline abdominal incision was also made in the latter two rats to 
allow access to the urinary bladder for urine collection.  The microdialysis probe was inserted 
into the cranial guide cannula; infusion of sterile artificial CSF was begun at 2 μg/min (in the 
third rat, infusion was increased to 2.5 μg/min after 90 minutes).  After 30 minutes of CSF 
infusion, the distal 2 mm of the animal’s tail was removed, and a tail blood sample was collected 
using a SAFE-T-FILL125 μL EDTA mini capillary tube (Ram Scientific, Yonkers, NY).  A 
loading dose of fluorescently-labeled laminarin, 1 mg/kg, was given via the intravenous line.  
Infusion of laminarin, 0.25 mg/kg/hr, was begun immediately following the loading dose.  The 
laminarin was infused for 5 hours; CSF samples were collected over 30-minute increments and 
blood samples were obtained every 30 minutes.  In the latter two rats, urine was also drawn from
the urinary bladder using a needle and syringe.  Throughout the procedure, rats were closely 
monitored to assess level of sedation.  When the laminarin infusion was completed, CSF infusion 
was also stopped.  Rats were then euthanized by exsanguination.  In the fourth rat, 75 µg
methylene blue was introduced into the guide cannula to mark its placement.  Two lateral cranial 
incisions were made through each animal’s skull cap, the cannula and acrylic cap were removed 
from each brain, and the brains were harvested and stored in 10% buffered formalin phosphate
(Fisher Scientific, Pittsburgh, PA).
Experimental Protocol for Surgical Injection of Glucan Phosphate
On the day of the procedure, the rats were sedated with isoflurane (Baxter, Deerfield, IL), 
then maintained on a combination of isoflurane and oxygen administered through a nose mask 
for the duration of the procedure, which provided constant anesthesia as well as assisting with 
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regular respiration.  The animals were kept on a warm-water bed throughout the procedure to 
maintain proper body temperature.  When the animal was under anesthesia, as determined by 
slow rhythmic breathing and lack of response to hindpaw pinching, sterile 5% dextrose (D5) 
solution was given SQ to aid in maintaining hydration and urine production.  Two areas of the 
animal’s skin were shaved: one approximately 4 cm in diameter at the lateral base of the neck, 
and the other approximately 3 cm in diameter on the abdominal midline.   On the abdomen, a 
midline incision was made to expose the urinary bladder for urine collection.  At the base of the 
neck, an incision was made to expose the left jugular vein, and an intravenous line was 
established.  The distal 2 mm of the animal’s tail was removed to allow for blood sampling.  
Control urine and tail blood samples were obtained.  Fluorescently-labeled glucan phosphate, 1 
mg/kg using a solution of 1 mg/mL in phosphate buffered saline (PBS), was injected directly into 
the left jugular vein.  After injection, tail blood samples were collected in SAFE-T-FILL 125 µL 
EDTA mini capillary tubes every 15 minutes during hour 1, every 30 minutes during hour 2, and 
every 60 minutes following hour 2 through hour 6.  Urine samples were collected every hour 
during the 6 hours.  Hydration was maintained through tap water administered via oral gavage 
and through SQ injections of D5.  Throughout the procedure, rats were closely monitored to 
assess level of sedation.  After 6 hours, the experiment was terminated and animals were 
euthanized by exsanguination.
Experimental Protocol for Intravenous Injection of Glucans
The distal 2 mm was removed from each animal’s tail to allow for blood sample 
collection.  Control tail blood samples were drawn from each rat using 125 µL SAFE-T-FILL 
EDTA mini capillary tubes.  Rats were temporarily anesthetized with isoflurane; the 
fluorescently-labeled glucans, at a dose of 1 mg/kg using a solution of 1 mg/mL in PBS, were 
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administered intravenously in the retro-orbital space.  Rats were immediately placed into 
individual metabolic cages with water available ad libitum.  Tail blood was drawn at 0.25, 0.5, 
0.75, 1, 1.5, 2, 3, 4, 5, and 6 hours following dose.  Urine was collected throughout the 
experiment via the metabolic cage.  At 6 hours, rats were placed back into their original cages 
and fed.
Experimental Protocol for Oral Administration of Glucans
The distal 2 mm of each animal’s tail was removed, and control tail blood samples were 
collected from each rat using 125 μL SAFE-T-FILL EDTA mini capillary tubes.  The 
fluorescently-labeled glucans, at a dose of 0.95 mg/kg using a solution of 0.95 mg/mL in water, 
were administered using an oral gavage technique.  Rats were immediately placed into individual 
metabolic cages with water available ad libitum.  Tail blood was collected at 0.25, 0.5, 0.75, 1, 
1.5, 2, 3, 4, 5, and 6 hours following dose.  Urine was collected throughout the experiment via 
the metabolic cage.  At 6 hours, rats were euthanized with carbon dioxide.  Blood was drawn 
from the vena cava into EDTA-treated Vacutainer tubes and centrifuged; plasma was removed 
and frozen for later analysis.  Kidneys and a section of jejunum (approx. 4 cm) were removed 
and placed in 4% paraformaldehyde for later histological analysis.
Experimental Protocol for Co-Administration of Glucan Phosphate and Lipopolysaccharide A
Rats were administered ultra-pure lipopolysaccharide A (LPS) from Escherichia coli
0111:B4 (List Biological Laboratories, Inc., Campbell, CA), 1 mg/kg intraperitoneally (IP), and 
allowed to rest for 1 hour.  After 1 hour, fluorescently-labeled glucan phosphate was given orally 
at a dose of 0.95 mg/kg, using a 0.95 mg/mL solution in water.  The distal 2 mm of each 
animal’s tail was removed, and tail blood samples were collected in 125 μL SAFE-T-FILL 
EDTA mini capillary tubes at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, and 6 hours following dose.  At 6
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hours, rats were euthanized with carbon dioxide.  Urine was drawn from the bladders with a 
sterile needle and syringe; urine was unobtainable from the remaining three rats.  Blood was 
drawn from the vena cava into 4.0 mL EDTA BD Vacutainer tubes (Becton, Dickenson and 
Company, Franklin Lakes, NJ) and centrifuged at 2000 rpm using a Sorvall Legend RT benchtop 
centrifuge (Thermo Scientific, Waltham, MA); plasma layer was removed and frozen for later 
analysis.
Comparison of Administration Methods and Co-Administration of LPS
Three animals were employed for the experiment.  One rat was administered ultra-pure
lipopolysaccharide A (LPS), 1 mg/kg IP, and allowed to rest for 1 hour.  After an hour, the LPS-
dosed animal, as well as one other animal, were administered fluorescently-labeled glucan 
phosphate orally at a dose of 1 mg/kg, using a 1 mg/mL solution in water.  The distal 2 mm of 
the tail was removed from the remaining animal and a control blood sample was obtained in a 
heparinized micro-hematocrit capillary tube.  This animal was anesthetized with isoflurane and 
administered glucan phosphate at a dose of 1 mg/kg IV retro-orbitally, using a 1 mg/mL solution 
in PBS.  Tail blood was drawn from the orally-dosed animal at 5, 10, 15, 20, 30, 45, 60, 90, and 
120 minutes following dose, collected in heparinized micro-hematocrit capillary tubes (Fisher 
Scientific, Pittsburgh, PA).  Blood samples were immediately centrifuged and plasma layer 
separated into a microcentrifuge tube.  After 2 hours, rats were anesthetized with carbon dioxide.  
Blood was drawn from the posterior vena cava into EDTA BD Vacutainer tubes and centrifuged;
plasma was removed and frozen for later analysis.  Urine was drawn from the bladder and stored 
in microcentrifuge tubes.  Kidneys were removed from the orally-dosed animal, and a section of 
jejunum was removed from the intravenously-dosed animals; the tissues were placed in 4% 
paraformaldehyde for histological analysis.  Rats were then euthanized with carbon dioxide.
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Detection of Fluorescent Glucans in Whole Tissues
Two animals were administered fluorescently-labeled oral glucan phosphate at a dose of 
1 mg/kg using a 1 mg/mL solution in water.  Two hours post-administration, animals were 
euthanized with carbon dioxide.  Kidneys were removed...  Kidney sections were submitted to 
the histology laboratory of the Department of Pathology (East Tennessee State University, 
Johnson City, TN) for embedding, sectioning, and staining or for frozen sectioning and staining.  
Various fixatives were employed, one per tissue sample: 100% methanol, 4% paraformaldehyde, 
HistoChoice fixative or periodate-lysine-paraformaldehyde (PLP) fixative; tissue for frozen 
section was fresh frozen using OCT compound.  Sytox green was used as a counter-stain.
Detection of Fluorescent Glucans in Plasma and Urine
Blood samples were centrifuged at 2000 rpm for 10 minutes.  Samples from plasma, 
CSF, and urine, as well as standards and controls, were pipetted into COSTAR black 96-well
microplates (Corning Life Sciences, Lowell, MA) and analyzed on a SpectraMax Gemini XPS
Plate Reader (Molecular Devices, Sunnyvale, CA) using SoftMax Pro software  For the 
experiments using glucans labeled with AlexaFluor 647,  the microplate reader parameters were 
set at an excitation of 645 nm and emission of 670 nm.  For the experiments using glucans 
labeled with AlexaFluor 488, the excitation was 485 nm and the emission was 520 nm.  For the 
experiments using glucans labeled with AlexaFluor 555, the excitation was 545 nm and the 
emission was 570 nm.  
Chromatography
Each urine sample was subjected to size-exclusion chromatography for peak 
determination and fractionation.  Briefly, a portion of each urine sample was injected into an 
ÄKTA purifier 10 (Amersham Biosciences, Piscataway, NJ) and passed through a desalting 
33
column (molecular weight cutoff of 5000 Da). The sample was fractionated based on volume 
into a COSTAR black 96-well microplate, to separate free fluorescence from bound.  The 
subsequent microplates were analyzed on a FLUOstar Galaxy Plate Reader with the appropriate 
parameters as described above.
Determination of Glucan Molecular Mass
From the chromatography microplates in one experiment, the samples representative of 
the higher molecular weight peak, or peak 1, were combined and lyophilized; the molecular mass 
was then determined by gas permeation chromatography/multi-angle laser light scattering 
(GPC/MALLS).  In each case, the total volume of the fraction to be combined and lyophilized 
was 3.5 mL.
Verification of Glucan Structure Presence in Urine
On the day of the procedure, the animal was sedated with isoflurane then maintained on a 
combination of isoflurane and oxygen administered through a nose mask for the duration of the 
procedure, which provided constant anesthesia as well as assisting with regular respiration.  The 
animal was kept on a warm-water bed throughout the procedure to maintain proper body 
temperature.  When the animal was under anesthesia, as determined by slow rhythmic breathing 
and lack of response to hindpaw pinching, 0.5cc tap water was given by oral gavage.  An area 
approximately 4 cm in diameter at the lateral base of the neck was shaved.  An incision was 
made to expose the left jugular vein, and an intravenous line was established.  A bolus injection 
of unlabeled glucan phosphate, 2 mg/kg, was given through the IV line.  Immediately following 
the bolus, an infusion of glucan phosphate, 1 mg/kg/hr, was begun through the IV line.  Sterile 
5% dextrose solution (D5), 10cc, was administered SQ after beginning the infusion.  Urine 
samples were collected periodically during the experiment and combined.  Throughout the 
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procedure, rats were closely monitored to assess level of sedation.  After 6 hours, the experiment 
was terminated, remaining urine was collected, and animal was euthanized by exsanguination.  
Control urine samples were obtained from age- and weight-matched Sprague-Dawley rats, 
unfasted.  Urine was prepared for nuclear magnetic resonance spectroscopy (NMR) to confirm 
the presence of glucans in the urine.  500 μL from the experimental and control urine samples, as 
well as 500 μL control urine spiked with 2.5 mg/mL glucan phosphate, were pipetted into
separate NMR tubes and submitted to Doug Lowman, PhD, Eastman Chemical Company for 
1H-NMR spectroscopy and interpretation.  Dr. Lowman’s method was as follows: 
Briefly, proton NMR spectral data were collected using a JEOL Model Eclipse+ 600 
NMR spectrometer operating at 80 ºC in 5-mm OD NMR tubes.  For each sample, about 
20 mg of isolate was dissolved in 1–mL of dimethyl sulfoxide-d6 (DMSO-d6) at 80 ºC. 
For the liquid urine samples, about 200 μL DMSO-d6 was combined with about 800 μL 
of liquid urine at room temperature.  Proton chemical shifts were referenced to the 
residual DMSO-d6 proton resonance at 2.50 ppm.  Generally, NMR spectral collection 
and processing parameters were the following: 25 ppm spectral width centered at 7.5 
ppm, 32768 data points, 1024 scans, 15 sec relaxation delay, 2.18 sec acquisition time, 
and exponential apodization.  
Remaining urine was lyophilized and stored.  A portion of one urine sample was also submitted 
to the Department of Pathology at East Tennessee State University for urinalysis.
Data Analysis
Results from fluorescence spectroscopy and ÄKTA chromatography were evaluated 
using Excel 2003 (Microsoft Corporation, Redmond, WA) and Prism 5.01 (GraphPad Software, 
La Jolla, CA).  Statistical analysis was performed using GraphPad statistical calculators.  To 
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determine statistical significance between control and treated groups, a 95% confidence interval 
was calculated based on the mean and SEM.  Significance was assumed when the treated group 
demonstrated a 95% confidence interval above, and not including, zero.
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CHAPTER 3
RESULTS
Laminarin Microdialysis
Laminarin was initially chosen for the study of glucan transport across the blood-brain 
barrier due to its relatively small molecular weight (~7700 Da) compared to other glucans.  Upon 
analysis of the samples obtained, no fluorescence was detected in any of the cerebrospinal fluid 
samples; however, fluorescence was detected in the plasma samples, indicating the presence of 
laminarin (data not shown).  From these results, we concluded that laminarin was not transported 
across the blood-brain barrier into the cerebrospinal fluid but was still present in the vascular 
circulation.  During the experiment with the third rat, we noticed that the urine had a greenish 
tint; we hypothesized that this could indicate the presence of laminarin in the urine, because the 
fluorescent 647 label on the laminarin gave the L647 solution a blue color.  Because of this 
observation, we collected urine periodically throughout the experiment in addition to 
cerebrospinal fluid and plasma from the fourth and fifth animals; six urine samples were 
collected in total from the two animals.  Upon fluorescence spectroscopy, a significantly high 
level of fluorescence was detected in the urine samples, suggesting the presence of laminarin in 
the urine (Fig. 6).
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Figure 6.  Laminarin (Lam) fluorescence is present in urine following intravenous infusion.  
Higher levels of fluorescence were observed in the samples from treated animals as compared to 
control animals.  Data represented is mean ± SEM; 95% CI is 575 to 1931 mcg/mL; N=6.
Excretion of Intravenously-Administered Glucans
Glucan Phosphate
Following the results of the intravenous laminarin experiment, we wanted to investigate 
whether the observed glucan excretion was molecular-weight dependent.  To test this hypothesis, 
we administered glucan phosphate intravenously; this polysaccharide has a higher molecular 
weight than laminarin (150,000 Da vs. 7700 Da).  As seen in Figure 7, significance fluorescence 
was detected in the urine samples, suggesting the presence of glucan phosphate in the urine.
We subjected a portion of each urine sample to size exclusion chromatography using a 
desalting column with a molecular weight cutoff of 5000 Da.  Given that the molecular weight of 
glucan phosphate is approximately 157,000 Da, and the molecular weight of the AlexaFluor 
label attached to the glucan is either 643 Da (for AlexaFluor 488) or 1250 Da (for AlexaFluor 
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Figure 7.  Glucan phosphate (GP) fluorescence is present in urine following intravenous 
injection.  Higher levels of fluorescent glucan phosphate were observed in the samples from 
treated animals as compared to control animals.  Data represented is mean ± SEM; 
95% CI is 50 to 119 mcg/mL; N=5.
555 or 647), size exclusion chromatography provided an efficient means of separating the free 
fluorescent label from the fluorescent label still bound to the glucan molecules.  In other words, 
the chromatography column was used to demonstrate whether the fluorescence observed in the 
urine samples originated from glucan molecules or from free fluorescent label that had been 
separated from the glucan and excreted on its own.  Any molecules greater than 5000 Da came 
off the column in the first elution fraction of four mL; the remaining elution fractions contained 
molecules with molecular weights less than 5000 Da.  Following analysis of these fractions by
fluorescence spectroscopy, the results demonstrated that 66 ± 2% of fluorescence was observed 
in the first elution fraction, indicating that approximately 66% of the fluorescent molecules in the 
urine samples were larger than 5000 Da (Fig. 8).  
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Figure 8.  Chromatographic analysis of glucan phosphate (GP) fluorescence in urine following 
intravenous injection.  The shaded peak denotes the first elution fraction containing molecules 
larger than 5000 Da; 66% of fluorescence was contained in this fraction.  N=7.
To confirm that this fraction contained the injected glucan phosphate, we also analyzed a 
portion of each urine sample by gel permeation chromatography and multi-angle laser light 
scattering (GPC/MALLS), allowing for an approximation of the molecular weight of the 
molecules in solution.  The light-scattering signal and refractive index detected by GPC/MALLS 
are shown in Figure 9.  As seen in Table 4, GPC/MALLS confirmed that the majority of the 
molecules were of low molecular weight.  These data, taken together, support glucan phosphate 
excretion in the urine following polysaccharide metabolism.
40
Figure 9.  The majority of excreted glucans are of lower molecular weight than the original 
polymer.  (a) denotes the light scattering signal; (b) denotes the refractive index.  Peak 1 
corresponds to a small amount of high molecular weight material, demonstrated by a relatively 
strong light scattering signal and low refractive index peak.  Peak 2 corresponds to a larger 
amount of low molecular weight material, demonstrated by a relatively weak light scattering 
signal and elevated refractive index peak.
Table 4.  Molecular weights of fluorescently-labeled glucan phosphate from urine as determined 
by GPC/MALLS.   The molecular weight of the first peak roughly corresponds to the size of the 
injected glucan phosphate.  The molecular weight of the second peak is significantly higher than 
the size of the fluorescent label, but significantly lower than the size of the glucan phosphate 
molecule.
Sample MW (first peak), Da MW (second peak), Da
1 144,000 38,600
2 162,000 2,860
3 189,000 6,870
4 189,000 3,710
Mean 171,000 13,010
SEM ±11,022 ±8,573
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Scleroglucan
At this point, we had evidence that small- and mid-weight glucans were excreted into the 
urine.  The next step was to test our highest-weight glucan, scleroglucan, which has an average 
molecular mass of approximately 1,000,000 Da.  As in the previous experiments, we injected the 
scleroglucan and collected urine samples for analysis (Fig. 10).  These urine samples also 
demonstrated a noticeable peak within the first elution fraction (containing molecules >5000 Da) 
following ÄKTA chromatography (Fig. 11).  This fraction represented 65 ± 11% of the total 
fluorescent molecules, indicating that approximately 65% of the fluorescence observed in the 
urine was from molecules larger than 5000 Da.
Figure 10.  Scleroglucan (SG) fluorescence is present in urine following intravenous injection.  
Higher levels of fluorescent scleroglucan were observed in the samples from treated animals as 
compared to control animals.  Data represented is mean ± SEM; 95% CI is 21 to 45 mcg/mL; 
N=6.
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Figure 11.  Chromatographic analysis of scleroglucan (SG) fluorescence in urine following 
intravenous administration.  The shaded peak denotes the first elution fraction containing 
molecules larger than 5000 Da; 65% of fluorescence was contained in this fraction.  N=6.
Laminarin
We now had data supporting glucan phosphate and scleroglucan excretion following 
intravenous administration, but we did not have data showing laminarin excretion following 
intravenous injection, only intravenous infusion.  Because infusion methods administer a much 
higher total amount of glucan than injection, we opted to repeat the intravenous injection 
experimental protocol using laminarin.  Results are similar to the injected glucan phosphate and 
scleroglucan experiments; significant fluorescence was detected in the urine samples (Fig. 12), 
while chromatography results indicated a clear peak in the first elution fraction (Fig. 13).  This 
fraction contained 88 ± 1% of total fluorescence, demonstrating that 88% of the fluorescence in 
the urine could be attributed to molecules larger than 5000 Da.
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Figure 12.  Laminarin (Lam) fluorescence is present in urine following intravenous injection.  
Higher levels of fluorescent laminarin were observed in the samples from treated animals as 
compared to control animals.  Data represented is mean ± SEM; 95% CI is 16 to 44 mcg/mL.  
N=6.
Figure 13. Chromatographic analysis of laminarin (Lam) fluorescence in urine following 
intravenous injection.  The shaded peak denotes the first elution fraction containing molecules 
larger than 5000 Da.  88% of fluorescent molecules remained in this fraction; N=6.
Excretion of Orally Administered Glucan Phosphate
We had shown at this point that glucans are excreted by the kidneys following both 
intravenous infusion and injection without regard to molecular weight, because the 
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polysaccharides appear to be metabolized into smaller fragments prior to excretion.  Our next 
step, therefore, was to look for glucan excretion following oral administration.   Glucan 
phosphate was chosen as the polymer for this study; because excretion appears to be independent 
of molecular size, we opted to use the glucan polymer most widely characterized and employed 
in our other studies.  Once again, our results indicated a significant level of fluorescence in the 
urine following oral administration (Fig. 14) with a clear first elution fraction peak demonstrated 
by size-exclusion chromatography (Fig. 15).  This fraction contained 53 ± 6% of the total 
fluorescent molecules.
Figure 14.  Glucan phosphate (GP) fluorescence is present in urine following oral administration.  
Higher levels of fluorescent glucan phosphate were observed in the samples from treated animals 
as compared to control animals.  Data represented is mean ± SEM;  95% CI is 36 to 62 mcg/mL.  
N=6.
Table 5 summarizes the results of our experiments with intravenously- and orally-
administered glucans.  Infused laminarin, as expected, resulted in the highest urinary glucan 
levels due to the high amount of glucan received by the animal.  Surgically injected glucan 
phosphate showed the next highest concentration of urinary glucan, followed by non-surgically 
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injected glucan phosphate and orally administered glucan phosphate.  Injected laminarin and 
scleroglucan had the lowest concentrations of urinary glucan, but were still significantly higher 
than controls.
Figure 15.  Chromatographic analysis of glucan phosphate (GP) fluorescence in urine following 
oral administration.  The shaded peak denotes the first elution fraction containing molecules 
larger than 5000 Da; 53% of fluorescence remained in this fraction.  N=4.
Table 5.  Summary of concentrations of glucans in urine following administration.  
Glucan
Method of 
administration
Dose received 
(based on 
animal’s weight)
Glucan 
concentration in 
urine, mcg/mL 
(mean ± SEM)
95% 
Confidence 
interval, 
mcg/mL
N (number 
of samples)
Laminarin IV infusion 300 to 362 μg 1253 ± 264 575 to 1931 6
Glucan 
phosphate
IV injection 396 to 422 μg 85 ± 13 50 to 119 5
Laminarin IV injection 288 to 328 μg 30 ± 5 16 to 44 6
Scleroglucan IV injection 238 to 248 μg 33 ± 5 21 to 45 6
Glucan 
phosphate
Oral gavage 396 to 456 μg 49 ± 5 36 to 62 6
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Table 5 continued.
Glucan Method of administration
Percent of fluorescent 
molecules in first elution 
fraction (>5000 Da),          
mean ± SEM
N (number of 
samples)
Glucan phosphate Intravenous injection 66 ± 2% 7
Laminarin Intravenous injection 88 ± 1% 6
Scleroglucan Intravenous injection 65 ± 11% 6
Glucan phosphate Oral gavage 53 ± 6% 6
Orally Administered Glucan Phosphate and Toxic Challenge
We had confirmed that glucans are excreted into the urine independent of molecular 
weight or administration method.  The next experiment was designed to test whether the 
presence of a shock-like state, induced by intraperitoneal administration of lipopolysaccharide A, 
would affect gastrointestinal permeability to glucans, thus affecting absorption and excretion.  
LPS is an endotoxin contained in the outer membrane of gram-negative bacteria and, as such, 
triggers the innate immune system to secrete pro-inflammatory cytokines.  The use of LPS is 
widely accepted as a method to model septic shock in experimental animals. In our experiments, 
upon administration of LPS to the animals, symptoms of illness were observed within 5 minutes
and peaked within 60 minutes; these symptoms included lethargy, irritability and diarrhea. One 
unforeseen complication of using lipopolysaccharide A in the animals was a significantly 
decreased urine production due to dehydration and general malaise.  Due to this, very small 
amounts of urine were collected from three of the six animals; the other three animals did not 
produce any obtainable urine.  Nevertheless, two peaks are still clearly seen in the 
chromatography results, with a relatively strong first elution fraction (Fig. 16).  40 ± 2% of 
fluorescence was retained in this fraction.
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Figure 16.  Chromatographic analysis of glucan phosphate (GP) fluorescence in urine following 
oral administration and LPS challenge.  The shaded peak denotes the first elution fraction 
containing molecules larger than 5000 Da.  This fraction contained 40% of total fluorescence; 
N=3.
Varying Administration Methods in the Presence or Absence of Toxic Challenge
The final experiment was designed to compare methods of glucan administration in the 
presence or absence of a shock-like state induced by LPS.  One rat was administered oral glucan 
1 hour post-LPS administration; the other two rats were not challenged with LPS but were 
administered glucans using different methods (intravenous versus oral).  As seen in Figure 17, 
the animal that received intravenous glucan demonstrated the highest levels of urinary glucans, 
followed by the animal receiving oral glucan without challenge by LPS.  The animal challenged 
with LPS demonstrated the lowest urinary glucan concentration; however, this result was still 
higher than control urine.
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Figure 17.  Comparison of glucan phosphate (GP) fluorescence in urine with different 
administration methods and LPS challenge.  N=1 per group.
LPS(+)/PO: LPS-treated animal; oral glucan administration.  
LPS(-)/PO: No LPS treatment; oral glucan administration.  
LPS(-)/IV: No LPS treatment; intravenous glucan administration.  
When these urine samples were subjected to size-exclusion chromatography, the sample 
from the animal administered with oral glucan demonstrated an evident peak within the first 
elution fraction, similar to the previous experiments, as seen in Figure 18.  However, the samples 
from the orally-administered glucan animals, both in the presence and absence of LPS challenge, 
showed little to no peaks.  
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Figure 18.  Chromatographic analysis of glucan phosphate (GP) fluorescence in urine with 
different administration methods and LPS challenge.  The shaded peak denotes the first elution 
fraction containing molecules larger than 5000 Da.
Detection of Glucan Structure in Urine
To confirm the presence of glucan structure in the >5000 Da molecular fraction detected 
by our analyses with fluorescence spectroscopy, ÄKTA chromatography and GPC/MALLS, we 
prepared unlabeled glucan phosphate and administered it intravenously to one animal.  A portion 
of the liquid urine sample was then subjected to nuclear magnetic resonance spectroscopy 
(NMR). Another portion of the sample was lyophilized and also submitted for NMR.  Analysis 
and interpretation was provided by Dr. Doug Lowman.  Figure 19 shows the results of the 1H-
NMR analysis of the liquid urine samples.  There are not proton NMR resonances in the pure 
glucan spectrum [Fig. 19 (d)] that also appear in the other three spectra [Fig. 19 (a), (b), and (c)].  
Originally it was thought that the anomeric proton might be most diagnostic of the presence of 
glucan in the urine samples, but the anomeric proton does not appear clearly in any of the spectra 
from the urine samples, even the spiked sample.  It was then hypothesized that the largest 
resonance in the glucan spectrum might be diagnostically useful, but on examination even the
multiple resonance around 3.3 ppm does not appear in any of the urine samples.
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Figure 20 depicts the NMR spectra from the lyophilized urine samples.  From these 
spectra, is it clear that there is no evidence for glucan in the rat urine sample [Fig. 20 (b)].  
Resonances at 4.53 ppm (not shown) and about 3.3 ppm in the reference glucan [Fig. 20 (c)]
appear possibly to be present in the lyophilized rat urine sample.  Because the doublet resonance 
from glucan near 3.73 ppm is not as evident in the urine sample, it is not possible to 
unequivocally indicate that the NMR spectrum demonstrates the presence of glucan in the 
lyophilized rat urine sample.
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Figure 19.  Carbohydrate spectral region from 1H-NMR analysis of liquid urine samples.        
(a): control urine sample; (b): control urine sample spiked with 2.5 mg/mL glucan; (c): urine 
sample from the glucan-treated animal; (d): reference sample of pure (1→3)-β-D-glucan.
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Figure 20.  Carbohydrate spectral region from 1H-NMR analysis of lyophilized urine samples. 
(a): lyophilized control urine sample; (b): lyophilized urine sample from the glucan-treated 
animal; (c): reference sample of pure (1→3)-β-D-glucan.
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Interestingly, upon sample collection from the animal, the urine appeared cloudy; after 
storage at 40°F overnight, before samples were prepared for NMR analysis, the urine from the 
treated animal contained a cloudy precipitate appearing to be mid-density with respect to the 
remainder of the sample (Fig. 21).
Figure 21.  Presence of precipitate in urine from animal treated with unlabeled glucan phosphate 
for NMR analysis.
In addition to 1H-NMR spectroscopy, a portion of the urine sample containing unlabeled 
glucan phosphate was submitted for urinalysis to identify the parameters of the sample and to 
establish possibilities for the precipitate observed in the sample.  Results were unremarkable and 
did not provide any identity for the precipitate (data not shown).
Presence of Fluorescent Glucans in Whole Tissue
To determine if glucans were being trapped within the kidneys, we submitted kidneys 
from one animal following intravenous glucan phosphate administration for histological slide 
preparation and counterstaining.  Various tissue fixation and mounting methods were employed 
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to determine if fluorescent glucans were present in the tissue sections; one fixative was used per 
tissue sample.  When sections were examined by fluorescence microscopy, no fluorescence was 
detected above background level in any of the sections; however, this is not conclusive.  We 
believe there may be two possibilities for our observations: the fixatives used may have caused 
the glucans to leach out of the tissues prior to fixation and staining, or the glucans are not being 
retained within the kidney structure.  The latter possibility is more likely because multiple 
fixatives were tested and no fluorescence was detected in any case.
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CHAPTER 4
DISCUSSION
Renal (1→3)-β-D-Glucan Excretion
(1→3)-β-D-Glucans have been investigated in great detail in recent years.  Their 
numerous biological and immunological effects have been characterized as anti-tumor agents 
and anti-inflammatory substances as well as targets for anti-fungal pharmacologic treatment.  
The pharmacokinetic profiles of these diverse polymers have been well documented by our 
laboratory following both intravenous and oral administration.  This is the first study, however, 
to focus on the method of excretion for these polysaccharides.
It is evident from the data presented that (1→3)-β-D-glucans are excreted renally.  
Glucan phosphate, laminarin, and scleroglucan were all detected in the urine following both oral 
and intravenous administration.  Infused laminarin demonstrated significantly high levels of 
urinary fluorescence, averaging 1253 ± 264 μg/mL.  This was followed by injected glucan 
phosphate, averaging 85 ± 13 μg/mL of fluorescent glucan in the urine; oral glucan phosphate, 
averaging 49 ± 5 μg/mL of fluorescent glucan in the urine; and injected laminarin and 
scleroglucan, averaging 30 ± 5 and 33 ± 5 μg/mL of fluorescent urinary glucan, respectively.  
There is a possibility that the presence of side-chain branching, as seen in laminarin and 
scleroglucan molecules, may affect the rate or amount of renal glucan excretion; this is supported 
by the fact that laminarin and scleroglucan demonstrated lower levels of urinary glucans than 
either intravenous or oral glucan phosphate, even though oral glucan phosphate is known to have 
a very low bioavailability (0.5%, according to Rice et al. 2005).  This observation may also be 
accounted for by the fact that the animals used in the experiments with injected laminarin and 
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scleroglucan were of lower body weight than the animals used in the experiments with injected 
and oral glucan phosphate, influencing the amount of glucan administered.
Following oral administration of glucan phosphate, when compared to intravenously 
administered glucan phosphate, a lower percentage of the excreted glucans was observed as 
fragments greater than 5000 Da (53 ± 6% for oral, 66 ± 2% for intravenous).  This either 
signifies that a greater percentage of the oral glucan phosphate was catabolized prior to renal 
processing, compared to intravenous glucan phosphate; or that the oral glucan phosphate was 
cleaved into more, and therefore shorter, fragments than the intravenously administered polymer.  
This difference supports the hypothesis that cleavage of glucan molecules occurs in the intestine 
prior to or during absorption from the gastrointestinal tract by β-glucan receptors.  
Excretion of (1→3)-β-D-glucans appears to be affected in the presence of systemic 
shock.  Lower amounts of total fluorescence were observed in the urine following induction of 
shock-like state in the animals and oral administration of glucan phosphate, as well as a lower 
percentage of glucan molecules in the >5000 Da elution fraction: 40 ± 2%, as compared to 53 ± 
6% fluorescence in this fraction following oral administration of glucan phosphate in the absence 
of toxic challenge with LPS.  It is unclear at this point what causes the decreased concentration 
of glucan molecules in the urine with this model, but at least two possibilities exist.  First, the 
small amount of urine in each sample may have precluded reliable detection of fluorescence 
within the urine, causing abnormally low levels to be observed.  Secondly, the 
lipopolysaccharide-induced shock caused systemic effects, some of which were visible (lethargy, 
diarrhea) and some of which were internal and therefore not visible.  The internal effects may 
have included decreased absorption of glucan from the gastrointestinal lumen into the 
bloodstream, decreased metabolism of glucan molecules, or decreased filtration and secretion of 
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glucan fragments within the nephron; all of these possibilities would have been demonstrated by 
the low glucan levels detected in the urine.
Possible Catabolism of Glucan Molecules Prior to Excretion
All three polysaccharides, following excretion, were detected as fragments smaller than 
the molecular size of the administered polysaccharide regardless of administration method.  Our 
size-exclusion chromatography results indicated that 88 ± 1% of intravenous laminarin, 65 ± 2%
of intravenous glucan phosphate, 65 ± 11% of intravenous scleroglucan, and 53 ± 6% of oral 
glucan phosphate were excreted as molecules larger than 5000 Da; in the case of glucan 
phosphate, these molecules were smaller than the original polymer size as demonstrated by gel 
permeation chromatography and multi-angle laser light scattering analysis.  This observation 
suggests the possibility of glucan metabolism by the body prior to excretion by the kidneys.  The 
high incidence of molecules larger than 5000 Da within the laminarin sample was not expected.  
We had theorized that laminarin would demonstrate a smaller percentage of molecules in the first 
elution fraction; due to the polymer’s original size of 7700 Da, cleavage fragments would be 
more likely to be less than 5000 Da.  This finding suggests that laminarin is small enough that it 
does not require catabolism prior to renal processing but can be filtered into the nephron in its 
original conformation.
To elucidate whether the process of glucan metabolism occurs, the cellular site of this 
cleavage must be characterized.  (1→3)-β-D-glucans appear to be metabolized elsewhere in the 
body prior to being transported to the kidneys.  At least some of this catabolism appears to occur 
in the intestines, as supported by the data from the oral glucan experiments and discussed above.  
Cleavage of glucan molecules would allow for filtration of the smaller fragments through the 
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glomerular barriers and into the nephron for renal excretion.  With the glucan polymers present 
as smaller molecules, they have not only a lower molecular weight but also a shorter chain 
structure, giving them increased glomerular permeability. The proposed process of glucan 
cleavage would require a specific mechanism to drive metabolism of glucan molecules, such as 
one or more cellular cleavage mechanisms that recognize a specific sequence within the glucan 
molecule.
Filtration and Secretion of (1→3)-β-D-Glucans
From the introduction, recall that renal filtration of proteins and similar molecules is 
restricted by molecular size barriers in the peritubular capillary wall.  The globular nature of 
proteins hinders their ability to pass through these pores.  However, Asgeirsson et al. (2007)
reported that polysaccharides such as dextrans and glucans are more likely to be filtered, due to 
their linear structure, even though their molecular size may rival that of globular proteins.  
Laminarin, with its relatively small molecular weight of 7700 Da, is theoretically able to be 
freely filtered through the peritubular capillary wall of the glomerulus.  In contrast, with a 
molecular weight of approximately 1,000,000 Da, scleroglucan is much too large and long a 
polysaccharide to be able to pass through this barrier.  Glucan phosphate, at 157,000 Da, falls 
between these two polymers in terms of molecular size and may be permeable to the glomerular 
barriers in its original form, but this is not proven.  If large polysaccharides such as scleroglucan 
(and possibly glucan phosphate) are to be excreted, as seen by the data presented here, they must 
be either catabolized into smaller fragments that will not be hindered by the pore size in the 
capillary epithelium, as discussed above, or secreted into the lumen of the nephron by facilitated 
diffusion.  As a comparison, consider albumin, a plasma protein with a molecular weight of 
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69,000 Da.  Albumin is filtered into the glomerulus, then reabsorbed in the proximal tubule of 
the nephron only by binding to a protein complex on proximal tubule cells and initiating the 
endocytosis process (Lazzara and Deen, 2007).  A mechanism similar to that of albumin 
reabsorption may be responsible for glucan secretion into the tubular lumen for urinary excretion
and would likely involve previously-identified (1→3)-β-glucan receptors.  These receptors, 
including Dectin-1 and scavenger receptor A, have been identified and characterized by multiple 
research laboratories.  It is widely accepted that these specific receptors exist on cells of the 
innate immune system, such as macrophages and neutrophils, as well as select non-immune 
cellular sites including vascular endothelium.  Results from our studies support the existence of 
these or similar β-glucan-specific receptors within the nephron to facilitate diffusion of unfiltered 
glucans and glucan fragments into the lumen for urinary excretion.
Presence of Glucan Structure in Urine
Results from nuclear magnetic resonance spectroscopy showed no clear evidence 
regarding the presence of glucan in urine following intravenous administration.  The glucan 
phosphate structure could not be definitively identified in the urine sample from the treated 
animal.  However, this structure also could not be identified in the control urine sample that had 
been spiked with pure glucan phosphate prior to NMR analysis, suggesting this method may not 
be a reliable assay for detecting renally excreted glucans.  The glucan-specific NMR method has 
previously been used for identification and characterization of glucans within solution or within 
a matrix but not for glucan identification within clinical samples.  It is not clear why NMR could 
not detect the glucan structure in the urine samples, even the intentionally spiked sample, 
contradicting all other experimental results in this study which show the excretion of glucans into 
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the urine.  Therefore, this result neither supports nor refutes the evidence shown in the 
experiments performed.
Conclusions
We have confirmed that (1→3)-β-D-glucans are excreted into the urine following 
intravenous and oral administration.  Our data corroborate a pharmacokinetic profile involving 
metabolism of glucan polymers prior to arrival in the nephron, where they are filtered or possibly 
secreted into the tubular lumen and excreted within the urine. The results we present have 
significance in both the research and clinical arenas.
The data we present supporting renal excretion of β-glucans open a new area of glucan 
pharmacokinetics to be investigated: the parameters of excretion of (1→3)-β-D-glucans, 
including renal clearance and biotransformation.  With this information, a complete 
pharmacokinetic profile of three synthetic glucans - glucan phosphate, laminarin, and 
scleroglucan - could be compiled and used in the development and use of glucans for clinical 
application as anti-inflammatory or anti-tumor agents.  Secondly, understanding how glucans are 
handled within the body could also aid in the refinement of serum tests and development of urine 
tests for fungal infection.  Knowing that certain fungal strains shed β-glucans into the 
bloodstream as they multiply and spread systemically, and knowing from the data presented here 
that β-glucans are eventually excreted in the urine, clinical urine assays for fungal infection 
similar to the serum G-test could be developed.  Also, identification and characterization of 
potential β-glucan-specific receptors within the kidney structure would not only lead to a better 
comprehension of how glucans are handled within the renal system but would also provide new 
prospective targets for anti-fungal pharmacologic treatments.  Similarly, elucidating the 
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mechanism responsible for cleavage of β-glucan molecules would present another potential anti-
fungal therapeutic target.  Our data provide a better understanding of (1→3)-β-D-glucan 
handling within the body and supply the groundwork necessary for further glucan research and 
development.
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